VA
TGTX icon

Vident Advisory’s TG Therapeutics TGTX Stock Holding History

Vident Advisory’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594K Sell
10,811
-408
-4% -$16.7K ﹤0.01% 1273
2026
Q1 		$373K Buy
11,219
+1,702
+18% +$50.7K ﹤0.01% 1393
2025
Q4 		$284K Sell
9,517
-2,086
-18% -$68.1K ﹤0.01% 1398
2025
Q3 		$419K Sell
11,603
-2,271
-16% -$74.8K ﹤0.01% 1263
2025
Q2 		$499K Buy
13,874
+1,042
+8% +$38.8K 0.01% 1050
2025
Q1 		$506K Buy
12,832
+1,754
+16% +$59K 0.01% 1025
2024
Q4 		$333K Sell
11,078
-163
-1% -$4.68K 0.01% 1132
2024
Q3 		$263K Buy
+11,241
New +$246K 0.01% 1185

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Vident Advisory's TGTX Position: Q2 2026 in Review

Vident Advisory reduced its TG Therapeutics (TGTX) stake by 3.6% in Q2 2026, selling an estimated $16.7K and leaving 10,811 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

Vident Advisory first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Vident Advisory held 10,811 shares of TG Therapeutics worth $594K as of Q2 2026.
  • Vident Advisory sold 408 TG Therapeutics shares in Q2 2026, an estimated $16.7K.
  • TG Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1273 holding.
  • Vident Advisory first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.